GlassScriptPhysician profile
Ming-Swang Lok
NPI 1548752371
$2,235.92
in general payments reported to CMS, 2019-2025
33 companies · $17.66 in 2025
The $17.66 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,780 · 2020: $393 · 2024: $45.11 · 2025: $17.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $62.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $62.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $276.78 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $263.75 | 2019-2020 | |
| Pfizer INC. | $207.67 | 2019-2020 | |
| Astellas Pharma US INC | $157.02 | 2019 | |
| Amgen INC. | $125.77 | 2019-2020 | |
| Incyte Corporation | $111.02 | 2019-2020 | |
| Abbvie INC. | $104.00 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.90 | 2019 | |
| Janssen Biotech, INC. | $83.28 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $78.15 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.02 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $54.24 | 2019-2020 | |
| Verastem, INC. | $49.60 | 2019 | |
| Merck Sharp & Dohme LLC | $49.30 | 2019 | |
| Amag Pharmaceuticals, INC. | $46.11 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $42.27 | 2019 | |
| Janssen Pharmaceuticals, INC | $42.10 | 2019 | |
| Csl Behring | $42.07 | 2019 | |
| Dendreon Pharmaceuticals LLC | $33.90 | 2019 | |
| Puma Biotechnology, INC. | $33.76 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.26 | 2019 | |
| Genentech USA, INC. | $27.66 | 2019 | |
| Secura Bio, INC. | $26.81 | 2019-2020 | |
| Spectrum Pharmaceuticals INC. | $24.35 | 2019 | |
| Array Biopharma INC | $22.83 | 2019 | |
| Exelixis INC. | $22.21 | 2019 | |
| Eisai INC. | $18.98 | 2019 | |
| Rigel Pharmaceuticals, INC. | $18.61 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.62 | 2020 | |
| Eusa Pharma (US) LLC | $16.07 | 2019 | |
| Celgene Corporation | $14.37 | 2019 | |
| Stemline Therapeutics INC. | $13.79 | 2020 | |
| Agios Pharmaceuticals, INC. | $12.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ming-Swang Lok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.